Target Patient Group Moderate to Severe
Note : Nomacopan dosing initiated Day 1. The BPDAI activity score used above is a composite measure including blisters/erosions, cutaneous urticaria/erythema, mucosal blisters/erosions. The global score also includes damage such as scarring which occurs during healing.
Format
JPEG
Source
Akari Therapeutics Plc